Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies

Why did Gemini file for a crypto IPO now? How does Trump-Musk feud affect Tesla’s stock? What impact could Musk’s SpaceX threats have? Why is Nvidia outperforming market expectations? How will Trump’s tariffs affect retail profits? What caused the latest US jobs report shift? Why is Circle’s IPO shaking the crypto market?

Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies

seekingalpha.com/article/4792866-amgen-stock-strategic-path-navigating-patent-expiries-with-promising-new-therapies-reiterate-buy

Summary
- Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses.
- Recent financials show solid revenue growth and improved margins, though net selling prices and legacy drugs like Enbrel remain under…

This story appeared on seekingalpha.com, 2025-06-06 06:31:14.